Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DFC004
MIFTS: 74

Deficiency Anemia

Categories: Blood diseases, Immune diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Deficiency Anemia

About this section

MalaCards integrated aliases for Deficiency Anemia:

Name: Deficiency Anemia 40 12 15
Anemia 40 12 74 29 54 6 42 44 15 62 39 17 71
Deficiency Anemias 12 71
Anaemia 12 15

Classifications:

MalaCards categories:
Anatomical: Immune diseases Blood diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:13121 DOID:2355
ICD9CM 34 281.9 285.9
MeSH 44 D000740
NCIt 50 C2869
SNOMED-CT 67 191125001 64593003
UMLS 71 C0002871 C0041782
Sources

Summaries for Deficiency Anemia

About this section
MedlinePlus : 42 If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body. Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction. Conditions that may lead to anemia include Heavy periods Pregnancy Ulcers Colon polyps or colon cancer Inherited disorders A diet that does not have enough iron, folic acid or vitamin B12 Blood disorders such as sickle cell anemia and thalassemia, or cancer Aplastic anemia, a condition that can be inherited or acquired G6PD deficiency, a metabolic disorder Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache. Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Deficiency Anemia, also known as anemia, is related to iron deficiency anemia and anemia, sideroblastic, 1, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Deficiency Anemia is HBA1 (Hemoglobin Subunit Alpha 1), and among its related pathways/superpathways are HIF-1 signaling pathway and HIF-1-alpha transcription factor network. The drugs Iron protein succinylate and Metformin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A hematopoietic system disease that is characterized by a decrease in the normal number of red blood cells.

PubMed Health : 62 About anemia: Anemia (uh-NEE-me-uh) is a condition in which your blood has a lower than normal number of red blood cells. Anemia also can occur if your red blood cells don't contain enough hemoglobin (HEE-muh-glow-bin). Hemoglobin is an iron-rich protein that gives blood its red color. This protein helps red blood cells carry oxygen from the lungs to the rest of the body. If you have anemia, your body doesn't get enough oxygen-rich blood. As a result, you may feel tired or weak. You also may have other symptoms, such as shortness of breath, dizziness, or headaches. Severe or long-lasting anemia can damage your heart, brain, and other organs in your body. Very severe anemia may even cause death.

Wikipedia : 74 Anemia (also spelled anaemia) is a decrease in the total amount of red blood cells (RBCs) or hemoglobin... more...

Sources

Related Diseases for Deficiency Anemia

About this section

Diseases related to Deficiency Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2831)
# Related Disease Score Top Affiliating Genes
1 iron deficiency anemia 34.0 TMPRSS6 TFRC TF SLC11A2 HJV HFE
2 anemia, sideroblastic, 1 33.7 TFRC SLC11A2 HJV HAMP GATA1
3 iron-refractory iron deficiency anemia 33.7 TMPRSS6 HJV EPO
4 diamond-blackfan anemia 33.7 TFRC RPS26 RPL11 GATA1 EPO
5 iron metabolism disease 33.6 TMPRSS6 TFRC TF SLC11A2 HJV HFE
6 anemia, congenital dyserythropoietic, type ia 33.5 TFRC HJV HAMP GATA1 EPO
7 congenital dyserythropoietic anemia 33.5 TFRC HFE HAMP GATA1 EPO
8 hereditary spherocytosis 33.3 TFRC SPTA1 HFE GATA1 G6PD
9 diamond-blackfan anemia 1 33.2 RPL11 GATA1 FOXP3
10 anemia, congenital dyserythropoietic, type ib 33.1 HAMP GATA1 G6PD
11 microcytic anemia 33.1 TMPRSS6 TFRC TF SLC11A2 HJV HFE
12 folic acid deficiency anemia 33.0 TFRC HAMP EPO CRP
13 atransferrinemia 32.9 TMPRSS6 TFRC TF SLC11A2 HJV HFE
14 bone marrow failure syndrome 1 32.6 TTR RPS26 FOXP3
15 aceruloplasminemia 32.5 TMPRSS6 TFRC SLC11A2 MT-ATP6 HJV HFE
16 hyperferritinemia with or without cataract 32.5 TF SLC11A2 HJV HFE HAMP
17 hemoglobin h disease 32.4 TFRC TF HBA1 HAMP G6PD EPO
18 cutaneous porphyria 32.2 HFE HAMP GATA1
19 porphyria cutanea tarda 32.2 TFRC TF HJV HFE HAMP EPO
20 thalassemia 32.1 LOC106099062 HBA1 GATA1
21 beta-thalassemia 32.1 TMPRSS6 TFRC TF SPTA1 LOC106099062 HJV
22 hemochromatosis, type 4 32.1 TMPRSS6 TFRC SLC11A2 HJV HFE HAMP
23 iron overload in africa 32.0 TF HJV HFE HAMP
24 celiac disease 1 32.0 TFRC HFE FOXP3 CRP
25 hypochromic microcytic anemia 31.9 TMPRSS6 TFRC TF SLC11A2 HJV HBA1
26 hemosiderosis 31.8 TF SLC11A2 HJV HFE HAMP EPO
27 chronic kidney disease 31.7 TTR TF HAMP EPO CRP
28 hemoglobinopathy 31.7 TFRC TF LOC106099062 HJV HFE HBA1
29 hemochromatosis, type 1 31.6 TMPRSS6 TFRC TF SPTA1 SLC11A2 HJV
30 hemolytic anemia 31.6 TFRC TF SPTA1 LOC106099062 HBA1 G6PD
31 rare hereditary hemochromatosis 31.6 TF HJV HFE HAMP
32 nutritional deficiency disease 31.4 TTR TMPRSS6 TFRC TF HJV HAMP
33 thalassemia minor 31.3 GATA1 EPO
34 type 2 diabetes mellitus 31.3 TTR TFRC HFE HBA1 HAMP FOXP3
35 restless legs syndrome 31.3 TFRC SLC11A2 HAMP EPO
36 alpha-thalassemia 31.3 TFRC LOC106099062 HFE HBA1 HAMP GATA1
37 sickle cell disease 31.3 TFRC LOC106099062 G6PD EPO
38 syphilis 31.2 HBA1 FOXP3 CRP
39 sickle cell anemia 31.2 LOC106099062 HBA1 G6PD EPO CRP
40 malaria 31.2 TFRC SPTA1 LOC106099062 HBA1 HAMP G6PD
41 polycythemia 31.1 TFRC HAMP EPO
42 pancytopenia 31.0 TTR FOXP3 EPO CRP
43 aplastic anemia 31.0 TFRC NRAS HFE GATA1 FOXP3 EPO
44 diabetes mellitus 31.0 TTR TF HFE HBA1 G6PD FOXP3
45 end stage renal disease 31.0 TTR HFE EPO CRP
46 rh isoimmunization 31.0 G6PD EPO
47 myelodysplastic syndrome 30.9 TFRC NRAS HFE HAMP GATA1 EPO
48 sideroblastic anemia 30.9 MT-ATP6 HFE HAMP
49 porphyria 30.9 TFRC HJV HFE HAMP GATA1 EPO
50 congenital hemolytic anemia 30.9 TF SPTA1 HAMP GATA1 G6PD EPO

Comorbidity relations with Deficiency Anemia via Phenotypic Disease Network (PDN): (show top 50) (show all 320)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Leukemia Acute Maxillary Sinusitis
Acute Myocardial Infarction Acute Pancreatitis
Acute Proliferative Glomerulonephritis Acute Vascular Insufficiency of Intestine
Adjustment Disorder Adrenal Gland Disease
Agammaglobulinemia, X-Linked Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alcoholic Neuropathy Alzheimer Disease
Amyloidosis Anemia, Autoimmune Hemolytic
Anus Cancer Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Asbestosis
Ascending Colon Cancer Aspergillosis
Atrioventricular Block Atrophic Gastritis
Atypical Depressive Disorder Autonomic Nervous System Disease
Bacteremia 2 Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bladder Cancer Bleeding Disorder, Platelet-Type, 11
Blepharitis Bronchiectasis
Bronchitis Bronchopneumonia
Bullous Pemphigoid Candidiasis
Cardiac Arrest Cardiogenic Shock
Cecal Benign Neoplasm Celiac Disease 1

Graphical network of the top 20 diseases related to Deficiency Anemia:



Diseases related to Deficiency Anemia
Sources

Symptoms & Phenotypes for Deficiency Anemia

About this section

UMLS symptoms related to Deficiency Anemia:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Deficiency Anemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 CRP EPO FOXP3 G6PD GATA1 HJV
2 hematopoietic system MP:0005397 10.1 EPO FOXP3 G6PD GATA1 HFE HJV
3 homeostasis/metabolism MP:0005376 10.1 CRP EPO FOXP3 G6PD GATA1 HFE
4 immune system MP:0005387 9.93 CRP EPO FOXP3 GATA1 HFE HJV
5 digestive/alimentary MP:0005381 9.91 FOXP3 HFE NRAS SPTA1 TFRC TMPRSS6
6 integument MP:0010771 9.65 EPO FOXP3 GATA1 HJV NRAS SLC11A2
7 liver/biliary system MP:0005370 9.32 EPO FOXP3 GATA1 HFE HJV NRAS
Sources

Drugs & Therapeutics for Deficiency Anemia

About this section

PubMed Health treatment related to Deficiency Anemia: 62

Treatment for anemia depends on the type, cause, and severity of the condition. Treatments may include dietary changes or supplements, medicines, procedures, or surgery to treat blood loss.

Drugs for Deficiency Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 666)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
4
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
5
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
6
Quinine Approved Phase 4 130-95-0 8549 3034034
7
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Halofantrine Approved Phase 4 69756-53-2 37393
16
Lactulose Approved Phase 4 4618-18-2 11333
17
Proguanil Approved Phase 4 500-92-5 4923
18
Ferrous gluconate Approved Phase 4 299-29-6
19
Cinacalcet Approved Phase 4 226256-56-0 156419
20
Artemether Approved Phase 4 71963-77-4 119380 9796294 68911
21
Lumefantrine Approved Phase 4 82186-77-4 6437380
22
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
23
Lopinavir Approved Phase 4 192725-17-0 92727
24
Doxazosin Approved Phase 4 74191-85-8 3157
25
Amlodipine Approved Phase 4 88150-42-9 2162
26
Ramipril Approved Phase 4 87333-19-5 5362129
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Clonidine Approved Phase 4 4205-90-7 2803
29
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
30
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
35
Desogestrel Approved Phase 4 54024-22-5 40973
36
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
37
Tocopherol Approved, Investigational Phase 4 1406-66-2
38
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
39
Deferiprone Approved Phase 4 30652-11-0 2972
40
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
41
Lactitol Approved, Investigational Phase 4 585-86-4 157355
42
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
43
Ferric maltol Approved Phase 4 33725-54-1
44
Tranexamic Acid Approved Phase 4 1197-18-8 5526
45
Ribavirin Approved Phase 4 36791-04-5 37542
46
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381 214348
47
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
48
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
49
Ibuprofen Approved Phase 4 15687-27-1 3672
50
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453

Interventional clinical trials:

(show top 50) (show all 2877)
# Name Status NCT ID Phase Drugs
1 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
2 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
3 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
4 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
5 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
6 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
7 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
8 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
9 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
10 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
11 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
12 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
13 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Erythropoietins (EPO);Sustained iron dextran supplementation
14 Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia Unknown status NCT02707757 Phase 4 Iron sucrose;Erythopoietin stimulating agent
15 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
16 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
17 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
18 Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561506 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
19 Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia Unknown status NCT03372447 Phase 4 Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
20 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
21 Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Unknown status NCT02838992 Phase 4 Rabbit ATG, (Genzyme);Cy;CsA
22 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02041299 Phase 4 Deferiprone;Deferoxamine
23 Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia Unknown status NCT01995331 Phase 4 cyclophosphamide,cyclosporine A
24 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
25 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
26 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
27 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
28 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
29 Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia Unknown status NCT03392298 Phase 4 Colla corii asini
30 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Unknown status NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
31 Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. Unknown status NCT02218437 Phase 4 MSC+ATG
32 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
33 Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial Unknown status NCT03229954 Phase 4 iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
34 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
35 Effect of Postoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561480 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
36 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
37 Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot) Unknown status NCT03295851 Phase 4 Ferric carboxymaltose;Ferrous Fumarate
38 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
39 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Unknown status NCT02984475 Phase 4 Metformin
40 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
41 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
42 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
43 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
44 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
45 Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD) Completed NCT00396435 Phase 4 Neorecormon
46 Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria Completed NCT02092766 Phase 4 artesunate;quinine
47 A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia Completed NCT02905539 Phase 4 Iron Isomaltoside 1000;Ferric Carboxymaltose
48 Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants (ETTNO)- a Blinded Randomized Controlled Multicenter Trial Completed NCT01393496 Phase 4
49 Vitamin B12 Supplementation in Addition to Folic Acid and Iron Improves Hematological and Biochemical Markers in Pregnancy: a Randomized Controlled Trial Completed NCT03522428 Phase 4
50 A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment Completed NCT00224068 Phase 4 Sodium ferric gluconate, ferrous sulfate, standard of care

Search NIH Clinical Center for Deficiency Anemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


darbepoetin alfa
Epoetin Alfa
Nandrolone
nandrolone decanoate
nandrolone phenpropionate
Oxymetholone
Sodium Ascorbate

Cochrane evidence based reviews: anemia

Sources

Genetic Tests for Deficiency Anemia

About this section

Genetic tests related to Deficiency Anemia:

# Genetic test Affiliating Genes
1 Anemia 29
Sources

Anatomical Context for Deficiency Anemia

About this section

MalaCards organs/tissues related to Deficiency Anemia:

40
Bone, Bone Marrow, Kidney, Heart, Liver, Myeloid, T Cells
Sources

Publications for Deficiency Anemia

About this section

Articles related to Deficiency Anemia:

(show top 50) (show all 35516)
# Title Authors PMID Year
1
Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. 42 61
33264546 2020
2
Severe anemia caused by dominant mutations in Krüppel-like factor 1 (KLF1). 42 61
33339573 2020
3
Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. 42
33382931 2020
4
Ribosomal protein S19 binds to its own mRNA with reduced affinity in Diamond-Blackfan anemia. 61 54
20395159 2010
5
Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. 61 54
20103588 2010
6
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. 54 61
20406921 2010
7
Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. 54 61
20438534 2010
8
Polyarthritis and anemia in a hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. 54 61
20353741 2010
9
Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV-1. 54 61
20196168 2010
10
Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. 54 61
20019408 2010
11
The first case of a class I glucose-6-phosphate dehydrogenase deficiency, G6PD Santiago de Cuba (1339 G > A), in a Chinese population as found in a survey for G6PD deficiency in northeastern and central China. 54 61
20200584 2010
12
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 61 54
20209848 2009
13
Hemolytic anemia after zopiclone overdose. 61 54
19821637 2009
14
Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. 61 54
19732172 2009
15
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. 61 54
19860200 2009
16
Serum transferrin receptors: Distribution and diagnostic performance in pre-school children. 54 61
19394251 2009
17
MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. 61 54
19591577 2009
18
Naturally acquired hemozoin by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism. 54 61
19427395 2009
19
Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. 54 61
19384207 2009
20
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 54 61
19663083 2009
21
Causes and consequences of inflammation on anemia management in hemodialysis patients. 61 54
19432697 2009
22
Role of interleukin-6 in the anemia of chronic disease. 54 61
18336871 2009
23
Current controversies in the management of the anemia of prematurity. 54 61
19167579 2009
24
Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells. 61 54
19265263 2009
25
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]. 54 61
19799194 2009
26
[Density-specific distribution of erythrocytes in different types of anemia]. 54 61
19253711 2009
27
Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report. 54 61
19100499 2008
28
[Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. 54 61
19099624 2008
29
Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. 61 54
18815191 2008
30
The anemia of ageing is not associated with increased plasma hepcidin levels. 54 61
18676162 2008
31
First synthesis of N-[(aziridin-2-yl)methyl]benzimidazolequinone and analysis of toxicity towards normal and Fanconi anemia cells. 54 61
18997962 2008
32
The role of oxidative stress in hemolytic anemia. 54 61
18991647 2008
33
Anemia and cerebral outcomes: many questions, fewer answers. 61 54
18806052 2008
34
Is obesity associated with anemia of chronic disease? A population-based study. 54 61
18719644 2008
35
Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis. 54 61
18837771 2008
36
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. 54 61
18547996 2008
37
Long-term treatment of anemia with recombinant human erythropoietin in familial amyloidosis TTR V30M. 61 54
18925459 2008
38
Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M. 61 54
18544472 2008
39
Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. 61 54
18758412 2008
40
C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. 61 54
18760763 2008
41
Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. 54 61
18640571 2008
42
Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. 54 61
18664788 2008
43
Anemia in monkey collagen-induced arthritis is correlated with serum IL-6, but not TNFalpha. 54 61
18309490 2008
44
Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo). 61 54
18923748 2008
45
Characterization of the N-glycosylation phenotype of erythrocyte membrane proteins in congenital dyserythropoietic anemia type II (CDA II/HEMPAS). 54 61
18166993 2008
46
[Anemia and lung cancer]. 54 61
18589288 2008
47
Similar cytokine responses and degrees of anemia in patients with Plasmodium falciparum and Plasmodium vivax infections in the Brazilian Amazon region. 54 61
18256207 2008
48
Anemia and iron status in young fertile non-professional female athletes. 61 54
18092176 2008
49
Anemia in chronic heart failure: etiology and treatment options. 61 54
18303527 2008
50
[Anemia in patients with cancer]. 54 61
18330028 2008
Sources

Variations for Deficiency Anemia

About this section

ClinVar genetic disease variations for Deficiency Anemia:

6 (show all 16)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FOXP3 NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln) SNV Pathogenic 379222 rs1057520529 X:49107901-49107901 X:49251440-49251440
2 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile) SNV Pathogenic 13426 rs76992529 18:29178618-29178618 18:31598655-31598655
3 LOC106099062 NG_000007.3:g.63632_71046del Deletion Pathogenic 15061 11:5247800-5255214 11:5226570-5233984
4 HBA1 NM_000517.6(HBA2):c.410T>C (p.Leu137Pro) SNV Pathogenic 15655 rs41469945 16:223580-223580 16:173581-173581
5 LOC106099062 NM_000518.5(HBB):c.79G>A (p.Glu27Lys) SNV Pathogenic 15161 rs33950507 11:5248173-5248173 11:5226943-5226943
6 LOC106099062 NM_000518.5(HBB):c.20A>T (p.Glu7Val) SNV Pathogenic 15333 rs334 11:5248232-5248232 11:5227002-5227002
7 ADAMTS15 Deletion Likely pathogenic 812956 11:114433313-131230466
8 MT-ATP6 NC_012920.1:m.8570T>C SNV Likely pathogenic 869162 MT:8570-8570 MT:8570-8570
9 SPTA1 NM_003126.4(SPTA1):c.2464+1G>A SNV Likely pathogenic 812890 rs774632615 1:158632491-158632491 1:158662701-158662701
10 NRAS NM_002524.5(NRAS):c.176C>A (p.Ala59Asp) SNV Likely pathogenic 812886 rs1570874751 1:115256535-115256535 1:114713914-114713914
11 GATA1 NM_002049.4(GATA1):c.680C>T (p.Ala227Val) SNV Likely pathogenic 812972 rs1602220307 X:48650811-48650811 X:48792404-48792404
12 RPL11 NM_000975.5(RPL11):c.142_143dup (p.Val49fs) Duplication Likely pathogenic 812883 rs1570566714 1:24019231-24019232 1:23692741-23692742
13 RPS26 NM_001029.5(RPS26):c.312+2T>A SNV Likely pathogenic 812897 rs1593023809 12:56437279-56437279 12:56043495-56043495
14 GATA2 NM_001145661.2(GATA2):c.971A>G (p.Lys324Arg) SNV Uncertain significance 523417 rs1480450110 3:128202749-128202749 3:128483906-128483906
15 YARS1 NM_003680.3:c.611A>C SNV Uncertain significance 986742 1:33256836-33256836 1:32791235-32791235
16 ANK1 NM_000037.4(ANK1):c.1948A>G (p.Met650Val) SNV Uncertain significance 373944 rs1057518790 8:41566346-41566346 8:41708828-41708828
Sources

Expression for Deficiency Anemia

About this section
Search GEO for disease gene expression data for Deficiency Anemia.
Sources

Pathways for Deficiency Anemia

About this section

Pathways related to Deficiency Anemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
HIF-1 signaling pathway 36
11.54 TFRC TF EPO
2
HIF-1-alpha transcription factor network 1
11.25 TFRC TF EPO
3
Ferroptosis 36
10.94 TFRC TF SLC11A2
4
Iron metabolism in placenta 1
10.34 TFRC TF SLC11A2 HAMP
5
Hfe effect on hepcidin production 1
9.77 TMPRSS6 HJV HFE HAMP